<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362644</url>
  </required_header>
  <id_info>
    <org_study_id>R20-010</org_study_id>
    <nct_id>NCT04362644</nct_id>
  </id_info>
  <brief_title>Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if imaging with [18F]FDG and [18F]DPA-714 using positron&#xD;
      emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis&#xD;
      in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help&#xD;
      physicians and researchers better understand how best to treat patients with IPF in the&#xD;
      future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlate quantitative PET measures of lung inflammation with [F-18]FDG and [F-18]DPA-714 to pulmonary function tests.</measure>
    <time_frame>screening to 48 hours post 2nd imaging visit.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PET/CT using PET ligands [18F]FDG and [18F]DPA-714</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714</intervention_name>
    <description>Study participants will undergo PET/CT with the glucose analogue [F-18]FDG and the TSPO ligand [F-18]DPA-714 in two separate imaging sessions.</description>
    <arm_group_label>PET/CT using PET ligands [18F]FDG and [18F]DPA-714</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 40-85 years old.&#xD;
&#xD;
          2. A diagnosis of IPF that fulfills ATS/ERS 2018 consensus criteria within 5 years.&#xD;
&#xD;
          3. Ability and willingness to give informed consent and adhere to study requirements.&#xD;
&#xD;
          4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC)&#xD;
             &gt;0.70.&#xD;
&#xD;
          5. High or mixed affinity binder for TSPO ligands based on genotyping for SNP rs6971.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute exacerbation of IPF within &lt;30 days&#xD;
&#xD;
          2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).&#xD;
&#xD;
          3. Diagnoses of current infection by clinical or microbial assessments.&#xD;
&#xD;
          4. Treatment for &gt;14 days within the preceding month with &gt;20 mg. prednisone (or&#xD;
             equivalent) or any treatment during the last month with a cellular immunosuppressant.&#xD;
&#xD;
          5. Subjects with prior radiation therapy to the thorax.&#xD;
&#xD;
          6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults,&#xD;
             and male predominant, so this will not be a frequent consideration.&#xD;
&#xD;
          7. Severe cardiovascular disease, defined as any of the following within the preceding 12&#xD;
             weeks: acute myocardial infarction or unstable angina, a coronary revascularization&#xD;
             procedure, or stroke.&#xD;
&#xD;
          8. Subjects with known liver disease.&#xD;
&#xD;
          9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.&#xD;
&#xD;
         10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.&#xD;
&#xD;
         11. Active cigarette smoking or vaping&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BSRT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Riddle, BSRT</last_name>
      <phone>205-934-6504</phone>
      <email>ariddle@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

